API
Intermediates
Custom synthesis
Polypetides
Nucleotide series
 Apixaban |
| Aprepitant |
| Bepotastine besylate |
| Bisoprolol Fumarate |
| Clomifene Citrate |
| Cyclophosphamide |
| Darifenacin HBr |
| Dronedarone Base |
| Dronedarone Hydrochloride |
| Dasatinib |
| Dasatinib monohydrate |
| Deferasirox |
| Febuxostat |
| Fesoterodine fumarate |
| Ivabradine Hydrochloride |
| Indacaterol |
| Lafutidine |
| Leucovorin Calcium |
| L-Leucovorin Calcium |
| Methotrexate |
| Mizolastine |
| Olopatadine Hydrochloride |
| Prasugrel Hydrochloride |
| Prasugrel base |
| Paricalcitol |
| Rivaroxaban |
| Silodoxin |
| Tamoxifen Citrate |
| Voriconazole |
| Voglibose |
| Calcitonin |
| Desmopressin |
| Terlipressin |
| Enfuvirtide(T-20) |
| Eptifibatide |
| Glucagon |
| Gonadorelin |
| Goserelin |
| Hexarelin |
| Leuprorelin |
| Melanotan¢ò |
| Octreotide |
| Sermorelin |
| Somatostatin |
| Thymopentin |
| ¦Á1Thymosin alpha-1 |
| Triptorelin |
| Buserelin |
| Deslorelin |
| Fertirelin |
| Nafarelin |
| Alarelin |
| Histrelin |
| Bivalirudin |
| Nesiritide |
| Exenatide |
| Pramlintide |
| Liraglutide |
| 1H-Inden-2-amine,5,6-diethyl-2,3-dihydro-,hydrochloride (1:1) |
| 4-(4-Aminophenyl)morpholin-3-one(For Ivabradine) |
| (S)-N-(2, 3-Epoxypropyl)phthalimide(For Ivabradine) |
| 3,4-dimethoxy-N-methyl-bicyclo[4.2.0]octa-1,3,5-triene-7-methanamine hydrochloride (For Ivabradine) |
| 3-(3-chloropropyl)-1,3-dihydro-7,8-dimethoxy-2H-3-Benzazepin-2-one(For Ivabradine) |
| Methanone, (2-butyl-5-nitro-3-benzofuranyl)[4-[3-(dibutylamino)propoxy]phenyl](For Dronedarone) |
| (5-Amino-2-butyl-3-benzofuranyl)[4-[3-(dibutylamino)propoxy]phenyl]-methanone dioxalate(For Dronedarone) |
| 2-Butyl-3-(4-methoxybenzoyl)-5-nitrobenzofuran(For Dronedarone) |
| 2-(n-Butyl)-3-(4-hydroxybenzoyl)-5-nitrobenzofuran(For Dronedarone) |
| N-(3-Chloropropyl)dibutylamine(For Dronedarone) |
| Ethyl 4-[(4-chlorophenyl)-2-pyridinylmethoxy]-1-piperidinecarboxylate(For Bepotastine) |
| 2-[(4-Chlorophenyl)(4-piperidinyloxy)methyl]-pyridine(For Bepotastine) |
| 2-[(4-chlorophenyl)(4-piperidinyloxy)methyl]-pyridine 4-nitrobenzoate |
| 6-ethyl-5-fluoro-4-hydroxypyrimidine(For Voriconazole) |
| 4-chloro-6-ethyl-5-fluoropyrimidine(For Voriconazole) |
| (2R,3S/2S,3R)-3-(4-Chloro-5-fluoro-6-pyrimidinyl)-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol hydrochloride (For Voriconazole) |
| (2R,3S/2S,3R)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol (Racemic Voriconazole) |
| 4-[(2-carboxyphenyl)methoxy]benzeneacetic acid (For Olopatadine) |
| 6,11-dihydro-11-oxo-dibenz[b,e]oxepin-2-acetic acid(For Olopatadine) |
| [3-(dimethylamino)propyl]triphenylphosphonium bromide hydrobromide (For Olopatadine) |
| N-{4-[4-(piperidinomethyl)pyridyl-2-oxy]-cis-2-butene}phthalimide Maleate(For Lafutidine) |
| 2-Chloro-4-(piperidin-1-ylmethyl)pyridine Oxalate(For Lafutidine) |
| p-nitrophenyl 2-(furfurylsulfinyl)acetate(For Lafutidine) |
| 5,6,7,8-tetrahydro-2-naphthol(For Liranaftate) |
| 2,3-dihydrobenzofuranyl-5-acetic acid(For Darifenacin) |
| 5-(2-bromoethyl)-2,3-dihydrobenzofuran (For Darifenacin) |
| (s)-2,2-diphenyl-2-(1-tosylpyrrolidin-3-yl)acetonitrile(For Darifenacin) |
| 2,2-Diphenyl-2-[(3S)-pyrrolidin-3-yl]acetamide L-(+)-tartrate (For Darifenacin) |
| Ethyl 2-(3-formyl-4-hydroxyphenyl)-4-methyl-5-Thiazolecarboxylate(For Febuxostat) |
| Ethyl 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-5-Thiazolecarboxylate(For Febuxostat) |
| KRP-203£¬2-Amino-2-(2-(4-(3-benzyloxyphenylthio)-2-chlorophenyl)ethyl)-1,3-propanediol hydrochloride |
| 1H-Indole-7-boronic acid |
| 38. 2-(Chloromethyl)-3-(trifluoromethyl)pyridine |
| Aromadendrin |
| Diphenyleneiodonium Sulfate |
| Ethyl 4-bromothiazole-2-carboxylate |
| 1-(2-Methylpyrimidin-5-yl)ethanamine |
| 3-Chloromethyl-1,2,4-oxadiazole |
| 5-Chloropyrazine-2-carbaldehyde |
| 2,3-Pyridinedicarboxylicacid,4-amino-,dimethylester |
| Methyl 3-amino-5,6-dimethylpyrazine-2-carboxylate |
| Ethyl 3-amino-4-methoxythieno[2,3-b]pyridine-2-carboxylate |
| Ethyl 3-amino-5-nitrothieno[2,3-b]pyridine-2-carboxylate |
| 1-(5-Methylpyrimidin-2-yl)ethanol |
| 7-Chloro-5-methoxy-Thieno[3,2-b]pyridine |
| 2-Bromo-7-chloro-thieno[3,2-b]pyridine |
| 5-Bromo-2,3-dihydro-1H-inden-2-ol |
| 5,7-Dichloro-pyrido[4,3-d]pyrimidin-4(3H)-one |
| 3-Bromo-5-methyl-1H-pyrazole |
| Lumiracoxib |
| Asenapine |
| Lurasidone |
| Lurasidone |
| Lurasidone HCl |
| Posaconazole |
| Alvimopan |
| Rivastigmine tartrate |
| Rasagiline mesylate |
| H-L-Asu-OH |
| 5-[(2R)-2-Aminopropyl]-1-[3-(benzoyloxy)propyl]-2,3-dihydro-1H-indole-7-carbonitrile (2R,3R)-2,3-dihydroxybutanedioate(for Silodoxin) |
| 2-[2-(2,2,2-Trifluoroethoxy)phenoxy]ethyl methanesulfonate(for Silodoxin) |
| Cyclopropyl-2-fluorobenzyl ketone (for Prasugrel) |
| 5,6,7,7a-Tetrahydrothieno[3,2-c]pyridin-2(4H)-one 4-methylbenzenesulfonate (for Prasugrel) |
| 5,6,7,7a-Tetrahydro-5-(triphenylmethyl)thieno[3,2-c]pyridinone(for Prasugrel) |
| 4-(2-Hydroxyethyl)oxyindole(forRopinirole) |
| 2,3,4,6-Tetra-O-benzyl-alpha-D-glucose (forVoglibose) |
| Tetrabenzyl-voglibose(forVoglibose) |
| 4,5-Dimethoxy-1-cyanobenzocyclobutane |
| (S)-4-[1-(4-Chlorophenyl)-1-(2-pyridyl) methoxy] piperidine (For Bepotastine) |
| Landiolol HCl |
| ((S)-2,2-Dimethyl-1,3-dioxolan-4-yl)methyl 3-(4-hydroxyphenyl)propanoate |
| (S)-(+)-Glycidyl nosylate |
| N-(2-Aminoethyl)-4-morpholinecarboxamide ethanedioate |
| methotrexate disodium |
| 2,4,5,6-Tetraaminopyrimidine sulfate |
| 2,4-diamino-6-(bromomethyl)pteridine |
| 2,3,4,6-Tetra-O-benzyl-D-glucopyranose(for Voglibose) |
| 8-benzyloxy-5-(2-bromoacetyl)-2-(1H)-quinolinone) (for indacaterol) |
| (3aR,4S,7R,7aS)-rel-Hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione(for Lurasidone) |
| (3R,4R)-3,4-Dimethyl-4-(3-hydroxyphenyl)piperidine(for Alvimopan) |
| (alphaS,3R,4R)-4-(3-Hydroxyphenyl)-3,4-dimethyl-alpha-(phenylmethyl)-1-piperidinepropanoic acid methyl ester(for Alvimopan ) |
| (R)-2-Benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoic acid(for Alvimopan) |
| Entecavir |
| 2-[(S)-(4-chlorophenyl)(4-piperidinyloxy)methyl]-pyridine (For Bepotastine) |
| (5R-cis)-Toluene-4-sulfonic acid 5-(2,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-yl)methyltetrahydrofuran-3-ylmethyl ester |
| 2-[(1S,2S)-1-Ethyl-2-bezyloxypropyl]-2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]-3H-1,2,4-triazol-3-one |
| Pidotimod |
| Raltitrexed |
| Pemetrexed disodium |
| olmesartan medoxomil |
| Doxofylline |
| Anagrelide Hydrochloride |
| Anagrelide |
| pramipexole dihydrochloride |
| Trans-(+/-)-11-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole-1-one |
| 11-chloro-2,3-dihydro-2-methyl-1H-dibenz[2,3;6,7]oxepino[4,5-c]pyrrol-1-one |
| (5-Chloro-2-phenoxyphenyl)acetic acid |
| Trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-Dibenz[2,3:6,7]oxepino[4,5-c]pyrrol-1-one |
| Cis-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-Dibenz[2,3:6,7]oxepino[4,5-c]pyrrol-1-one |
| Mixture of Trans and Cis-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-Dibenz[2,3:6,7]oxepino[4,5-c]pyrrol-1-one |
| 5-Chloro-2-Methyl-2,3-Dihydro-Benzo-[2,3:6,7]-Oxepino-[4,5-C]-pyrrole-(2H)-One |
| Dabigatran etexilate mesylate |
| Dabigatran etexilate |
| 3-[(3-Amino-4-methylaminobenzoyl)pyridin-2-ylamino]propionic acid ethyl ester |
| N-(4-Cyanophenyl)glycine |
| Benzoic acid, 4-(methylamino)-3-nitro |
| Ethyl 3-(pyridin-2-ylamino)propanoate |
| 2-(4-Methoxy-1,4-cyclohexadienyl)-2-propanol(for Nabilone) |
| 5-(1,1-Dimethylheptyl)resorcinol(for Nabilone) |
| 2-Hydroxyquinoline-4-carboxylic acid |
| Tetraisopropyl methylenediphosphonate(for Disodium clodronate) |
| Di(N-succinimidyl) adipate |
| TRI(ETHYLENE GLYCOL) DI-P-TOLUENESULFONATE |
| (S)-3-(5-(2-aminopropyl)-7-cyanoindolin-1-yl)propyl benzoate(2S,3S)-2,3-dihydroxysuccinate |
| 5-[(2R,S)-2-AMINOPROPYL]-1-[3-(BENZOYLOXY)PROPYL]-2,3-DIHYDRO-1H-INDOLE-7-CARBONITRILE |
| (R)-tetrahydrothiophen-3-ol |
| ethyl 4-(4-hydroxypiperidin-1-yl) butanoate |
| (S)-(4-chlorophenyl)(pyridine-2yl)methanol (S form) |
| ethyl 4-(4-bromoypiperidin-1-yl)butanoate |
| Benzothiophene-3-carboxylic acid |
| Edoxaban tosylate monohydrate |
| Edoxaban |
| 4,5,6,7-tetrahydro-5-Methyl-Thiazolo[5,4-c]pyridine-2-carboxylic acid hydrochloride |
| Carbamic acid, N-[(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl) amino]-2-oxoacetyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester |
| Carbamic acid,[(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl]-,1,1-dimethylethyl ester |
| N-[3-fluoro-4-[(methylamino)carbonyl]phenyl]-2-methyl-alanine |
| N-[3-fluoro-4-[(methylamino)carbonyl]phenyl]-2-methyl-alanine methyl ester |
| 4-Isothiocyanato-2-(trifluoromethyl)benzonitrile |
| Enzalutamide |
| Naphthalene,1-cyclopropyl-4-isothiocyanato- |
| THR-PHE-GLN-ALA-TYR-PRO-LEU-ARG-GLU-ALA |
| esinurad |
| (R)-3-aminobutan-1-ol |
| 1533519-85-5 |
| Apremilast |
| N-(1,3-dioxo-1,3-dihydro-isobenzofuran-4-yl)acetamide |
| 4-(4-cyclopropylnaphthalen-1-yl)-1H-1,2,4-triazole-5(4H)-thione |
| Acotiamide hydrochloride |
| 138530-94-6 |
| MK-4305 |
| FYX 051 |
| 6-Ethylchenodeoxycholic acid |
|
Our goal is to become a fully-integrated biopharmaceutical company and a leader in the discovery, development and commercialization of novel small molecule drugs. Key components of our strategy to achieve our corporate goals are outlined below.
Build and advance our product candidate pipeline. Through our drug discovery and development programs, we have created a broad pipeline of drug candidates spanning a range of therapeutic areas. We plan to continue to aggressively pursue the development and commercialization of these drug candidates. In addition, we believe that the breadth of our capabilities in drug discovery technology will enable us to continue to identify and develop additional drug candidates on an efficient and rapid basis.
Establish strategic alliances with academic institutes and leading pharmaceutical companies. We have established, and expect to continue to build upon, a broad set of strategic alliances with several academic institutes and leading pharmaceutical companies. These collaborations have enabled us to leverage our expertise into additional therapeutic areas, benefit from the therapeutic area expertise and commercial resources of our partners, and augment our financial resources.
Expand our development expertise. From our origins as a drug discovery organization, we have steadily expanded our capabilities in drug development. As we advance our product candidate pipeline, we plan to further augment our development team by adding additional personnel with experience in drug safety, regulatory affairs, statistical methods, project management and medical affairs.
Establish specialized sales and marketing capabilities. We plan to retain China and United States marketing and sales rights or co-promotion rights for our product candidates. |
